Skip to main content
SpringerLink
Log in

Response Assessment to Cancer Therapy

  • Chapter
  • First Online:
Practical Medical Oncology Textbook

Part of the book series: UNIPA Springer Series ((USS))

  • 3333 Accesses

Abstract

Cancer generically refers to a group of diseases showing an uncontrolled division of abnormal cells potentially having the ability to invade, through the blood and lymph systems, nearby tissues or spread to other parts of the body.

Cancer is one of the leading causes of morbidity and mortality worldwide.

In recent years several criteria have been developed for response assessment to cancer therapy.

RECIST (Response Evaluation Criteria in Solid Tumours) guide daily clinical practice for the management of patients with cancer.

Choi response criteria are used in patients with GIST treated by imatinib.

In the last years, the iRECIST have been developed for response assessment in trials testing immunotherapeutics.

Diagnostic criteria for cancer assessment change rapidly.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI J Nat Cancer Inst. 2000;92(3):205–16. https://doi.org/10.1093/jnci/92.3.205.

    Article  CAS  PubMed  Google Scholar 

  2. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

    Article  CAS  PubMed  Google Scholar 

  3. Tirkes T, Hollar MA, Tann M, et al. Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics. 2013;33(5):1323–41. https://doi.org/10.1148/rg.335125214.

    Article  PubMed  Google Scholar 

  4. Kim HD, Kim BJ, Kim HS, et al. Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis. Korean J Intern Med. 2019;34(3):608–17. https://doi.org/10.3904/kjim.2017.063. Epub 2018 Jan 17.

    Article  CAS  PubMed  Google Scholar 

  5. Nishino M, Guo M, Jackman DM, et al. CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of an emerging clinical tool. Acad Radiol. 2011;18(1):54–62. https://doi.org/10.1016/j.acra.2010.08.021. Epub 2010 Oct 30.

    Article  PubMed  Google Scholar 

  6. Mozley PD, Bendtsen C, Zhao B, et al. Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol. 2012;5(1):19–25. Epub 2012 Feb 1.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Zhao B, Oxnard GR, Moskowitz CS, et al. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res. 2010;16(18):4647–53. https://doi.org/10.1158/1078-0432.CCR-10-0125. Epub 2010 June 9.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Nishino M, Hatabu H, Johnson BE, et al. State of the art: response assessment in lung cancer in the era of genomic medicine. Radiology. 2014;271(1):6–27. https://doi.org/10.1148/radiol.14122524.

    Article  PubMed  Google Scholar 

  9. Wang J, Wu N, Cham MD, Song Y. Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol. 2009;193(4):1090–6. https://doi.org/10.2214/AJR.08.1367.

    Article  PubMed  Google Scholar 

  10. Fraioli F, Anzidei M, Zaccagna F, et al. Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience. Radiology. 2011;259(2):574–82. https://doi.org/10.1148/radiol.11100600. Epub 2011 Feb 25.

    Article  PubMed  Google Scholar 

  11. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet.

  12. https://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/understanding-targeted-therapy.

  13. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25(13):1753–9.

    Article  PubMed  Google Scholar 

  14. https://www.drugbank.ca/drugs/DB00619.

  15. Vincenzi B, Nannini M, Badalamenti G, et al. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. Ther Adv Med Oncol. 2018;10:1758835918794623. Published 2018 Aug 29. https://doi.org/10.1177/1758835918794623.

  16. https://www.cancer.org/cancer/gastrointestinal-stromal-tumor/about/what-is-gist.html.

  17. Choi H, Charnsangavej C, Faria SC, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG-PET findings. AJR Am J Roentgenol. 2004;183:1619–28.

    Article  PubMed  Google Scholar 

  18. Shankar S, van Sonnenberg E, Desai J, et al. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology. 2005;235(3):892–8. Epub 2005 Apr 15.

    Article  PubMed  Google Scholar 

  19. Dimitrakopoulou-Strauss A, Ronellenfitsch U, Cheng C, et al. Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. Clin Transl Imaging. 2017;5(3):183–97. https://doi.org/10.1007/s40336-017-0229-8. Epub 2017 May 3.

    Article  PubMed  PubMed Central  Google Scholar 

  20. https://www.cancer.gov/aboutcancer/treatment/types/immunotherapy#1.

  21. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166–82.

    Article  CAS  PubMed  Google Scholar 

  22. Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009;10:1185–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99:12293–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Tarhini AA. Tremelimumab: a review of development to date in solid tumors. Immunotherapy. 2013;5:215–29.

    Article  CAS  PubMed  Google Scholar 

  25. Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother. 2007;30:1–15.

    Article  PubMed  Google Scholar 

  26. Seymour L, Bogaerts J, Perrone A, et al. RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–52. https://doi.org/10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedicine, Neurosciences and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy

    Massimo Midiri, Patrizia Toia, Giuseppe La Tona, Massimo Galia & Giuseppe Lo Re

Authors
  1. Massimo Midiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrizia Toia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe La Tona
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Massimo Galia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giuseppe Lo Re
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Galia .

Editor information

Editors and Affiliations

  1. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

    Antonio Russo

  2. Oncology Department, University of Antwerp, Edegem, Belgium

    Marc Peeters

  3. Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy

    Lorena Incorvaia

  4. Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai System & Icahn School of Medicine, Mount Sinai, NY, USA

    Christian Rolfo

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Midiri, M., Toia, P., La Tona, G., Galia, M., Lo Re, G. (2021). Response Assessment to Cancer Therapy. In: Russo, A., Peeters, M., Incorvaia, L., Rolfo, C. (eds) Practical Medical Oncology Textbook. UNIPA Springer Series. Springer, Cham. https://doi.org/10.1007/978-3-030-56051-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-56051-5_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-56050-8

  • Online ISBN: 978-3-030-56051-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation